Genolution

Genolution Financial Debt Ratio

The Financial Debt Ratio of Genolution (225220.KQ) as of Oct 22, 2026 is 22.62 %. In the previous year, Financial Debt Ratio was 21.22 % — a change of 6.57% (higher).

Financial Debt Ratio

22.62 %

YoY

6.57%

Last updated:

Financial Debt Ratio of Genolution is 2024 22.62 % . Financial Debt Ratio of Genolution was 2023 21.22 % . It decreases by 6.57% higher compared to the previous year.

The Genolution Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2017
0.00 KRW
Jan 1, 2018
14.81 KRW
Jan 1, 2019
26.45 KRW
Jan 1, 2020
7.93 KRW
Jan 1, 2021
0.00 KRW
Jan 1, 2022
13.16 KRW
Jan 1, 2023
21.22 KRW
Jan 1, 2024
22.62 KRW
The Genolution Financial Debt Ratio history
YEARFinancial Debt RatioYoY
22.62 %+6.57%
21.22 %+61.28%
13.16 %—
0.00-100.00%
7.93 %-70.00%
26.45 %+78.65%
14.81 %—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Financial Debt Ratio of Genolution is 22.62 % in 2024.

Financial Debt Ratio of Genolution changed from 21.22 % to 22.62 %, representing a 6.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Genolution since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Genolution with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genolution

All Key Metrics — Genolution